New drug combo targets head and neck cancer with precision radiation
NCT ID NCT04105543
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 28 times
Summary
This early-phase study tested an experimental drug, CLR 131, that delivers radiation directly to cancer cells, combined with standard external beam radiation. The goal was to see if this combination is safe and can deliver a high dose of radiation to tumors in people whose head and neck cancer has come back. The study enrolled 12 participants and used imaging to measure how much radiation reached the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin, 53038, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.